Pipeline

February 21, 2020
Company Drug/Device Medical Condition Status
Atreca ATRC-101 Select solid tumor cancers phase 1 first patient dosed
AXIM Biotechnologies cannabinoid-based chewing gum with dronabinol chemotherapy-related symptoms phase 1 completed
Applied Genetic Technologies AGTC-501 X-linked retinitis pigmentosa phase 1/2 enrollment completed
Molecular Templates TAK-169 relapsed/refractory multiple myeloma phase 1 dosing initiated
Cyclo Therapeutics Trappsol Cyclo Niemann-Pick disease Type C phase 1/2 patient enrollment completed
Harbour BioMed HBM9161 autoimmune diseases phase 1 completed
ImmunogenX Latiglutenase (IMGX003) celiac disease phase 2b enrollment started
Aravive AVB-500 platinum-resistant recurrent ovarian cancer phase 1b enrollment started for higher dosage
BioXcel Therapeutics BXCL501 agitation in schizophrenia phase 2 trial initiated
RIBOMIC RBM-007 exudative age-related macular degeneration phase 2 first patient injected
DelMar Pharmaceuticals VAL-083 newly diagnosed, MGMT-unmethylated glioblastoma multiforme phase 2 final patient enrolled and dosed
Palatin Technologies topical PL9643 dry eye disease phase 2 initiated, first patient enrolled
Compugen COM701, in combination with nivolumab and BMS-986207 advanced solid tumors phase 1/2 plans for initiation
Dyve Biosciences DYV-700 acute gout phase 2 initiated, first patient enrolled
VBL Therapeutics VB-111 in combination with nivolumab metastatic colorectal cancer phase 2 initiated
SCYNEXIS ibrexafungerp vulvovaginal candidiasis phase 3 enrollment completed
Isofol Medical arfolitixorin metastatic colorectal cancer phase 3 first patient in Japan dosed
Alnylam Pharmaceuticals vutrisiran ATTR amyloidosis phase 3 enrollment completed
Axsome Therapeutics AXS-007 migraines phase 3 enrollment completed
Epizyme TAZVERIK (tazemetostat) follicular lymphoma priority review granted by the FDA
Seattle Genetics

Astellas Pharma		 PADCEV (enfortumab vedotin-ejfv) advanced bladder cancer Breakthrough Therapy designation awarded by the FDA
Cardiovalve Transcatheter Tricuspid Valve Replacement System tricuspid regurgitation Breakthrough Therapy designation awarded by the FDA
Horizon Therapeutics PROCYSBI (cysteamine bitartrate) nephropathic cystinosis new dosage form approved by the FDA
Agile Therapeutics Twirla (levonorgestrel and ethinyl estradiol) transdermal system female hormone deficiency approved by the FDA
Baudax Bio ANJESO (meloxicam injection) management of moderate to severe pain approved by the FDA
Bristol-Myers Squibb Opdivo (nivolumab) unresectable advanced or recurrent esophageal cancer that has progressed following chemotherapy approved by the Japan Ministry of Health, Labor and Welfare

 

Upcoming Events

Featured Products

Featured Stories

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here